Skip to content
Medical Health Aged Care

TOMORROW D-Esc VR tool Melbourne launch event – new workshop for de-escalating a behavioural emergency in a care setting

Dementia Australia 2 mins read

Tomorrow, Dementia Australia unveils D-Esc in Melbourne, a new innovative virtual reality (VR) training workshop for de-escalating a behavioural emergency in a care setting.        

D-Esc provides an immersive simulation, designed for frontline and health care professionals, to adopt an interactive approach to de-escalation training.

Join us to experience D-Esc – the first of its kind VR training workshop set to revolutionise the dementia care industry, as well as to hear about how Dementia Australia’s suite of technology is positively impacting the lives of people living with dementia and those caring for them.

B-roll, VR footage and BTS development footage and spokespeople available. Photo opportunities and interviews available at the event.

Date: Thursday 6 June 2024

Time: 9.30am arrival for a 10.00am – 11.30am event

Location: Melbourne Convention and Exhibition Centre, South Wharf

Speakers:

  • Danni Campbell-Manley, VIC State Manager, Aged & Community Care Providers Association
  • Dr Kaele Stokes, Executive Director Services, Advocacy and Research, Dementia Australia
  • Dr David Sykes, Director of Centre for Dementia Learning, Dementia Australia
  • Anne Fairhall, Dementia Australia Dementia Advocate

 

If you can attend, please email Gabrielle.Prabhu@dementia.org.au or contact 0447 253 583

Dementia Australia is the source of trusted information, education and services for the estimated more than 421,000 Australians living with dementia, and the more than 1.6 million people involved in their care. We advocate for positive change and support vital research. We are here to support people impacted by dementia, and to enable them to live as well as possible. No matter how you are impacted by dementia or who you are, we are here for you.

For support, please contact the National Dementia Helpline on 1800 100 500. An interpreter service is available. The National Dementia Helpline is funded by the Australian Government. People looking for information can also visit dementia.org.au

-Ends-

Media contacts: Gabrielle Prabhu, Media & Communications Advisor, Gabrielle.Prabhu@dementia.org.au, 0447 253 583

When talking or writing about dementia please refer to Dementia-Friendly Language Guidelines.

Note to Editors: We request, where possible, details for the National Dementia Helpline 1800 100 500 appear alongside news stories about dementia, as these stories often prompt questions or concerns:

If this story has prompted any questions or concerns, please call the National Dementia Helpline 1800 100 500 (24 hours, 7 days a week) or visit dementia.org.au.

More from this category

  • Medical Health Aged Care
  • 24/06/2024
  • 17:07
Takeda Pharmaceutical Company Limited

Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies

LIVTENCITY Is the First and Only Post-Transplant Anti-CMV Treatment Approved in Japan That Targets/Inhibits UL97 Protein Kinase1 CMV Is One of the Most Common…

  • Contains:
  • CharitiesAidWelfare, Medical Health Aged Care
  • 24/06/2024
  • 16:20
National Rural Health Alliance

Community-led innovation to revolutionise healthcare access in rural Australia

The National Rural Health Alliance (the Alliance) is delighted that the Minister for Health and Aged Care, the Hon Mark Butler, has today announced…

  • Contains:
  • Business Company News, Medical Health Aged Care
  • 24/06/2024
  • 12:25
Jane Morgan Management

Imugene (ASX:IMU) Doses First Patient in Pioneering Phase 1 onCARlytics Trial

Sydney, Australia, 24 June 2024: Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company, is thrilled to announce the dosing of the first patient in the intravenous (IV) infusion combination arm of its Phase 1 onCARlytics (CF33-CD19) clinical trial. This groundbreaking trial, named OASIS, is being conducted at City of Hope in California and is designed to transform the treatment landscape for patients with advanced solid tumors. The OASIS trial is a world-first, combining a CD19-expressing oncolytic virus with a CD19-targeting drug. The trial aims to recruit 40-45 patients with advanced solid cancers that have metastasized, with preliminary early combination data…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.